Get started
Author

Juliet María Enriquez-Puertas

Observed names: Enriquez Puertas, Juliet María, Enríquez Puertas, Juliet, Enríquez Puertas, Juliet M., Enríquez-Puertas, Juliet María, J. Enriquez-Puertas, J.M. Enriquez-Puertas, Juliet Enriquez, Juliet Enriquez-Puertas, Juliet Enríquez-Puertas, Juliet María Enriquez Puertas
Observed institution: AIDS United
ORCID: 0000-0002-3951-2498
Observed ORCIDs: 0000-0002-3951-2498, 0000-0002-8713-8875
OpenAlex ID: A5070540296
SARS-CoV-2 RBD-Tetanus Toxoid Conjugate Vaccine Induces a Strong Neutralizing Immunity in Preclinical Studies
2021 · Yury Valdes-Balbin, Darielys Santana-Mederos, et al. · ACS Chemical Biology · 86
PDF
A single dose of SARS-CoV-2 FINLAY-FR-1A vaccine enhances neutralization response in COVID-19 convalescents, with a very good safety profile: An open-label phase 1 clinical trial
2021 · Arturo Chang-Monteagudo, Rolando Ochoa-Azze, et al. · The Lancet Regional Health - Americas · 43
PDF
Safety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults
2022 · María Eugenia Toledo-Romani, Mayra García-Carmenate, et al. · Med · 29
PDF
Safety and immunogenicity of the FINLAY-FR-1A vaccine in COVID-19 convalescent participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial
2022 · Rolando Ochoa-Azze, Arturo Chang-Monteagudo, et al. · The Lancet Respiratory Medicine · 27
PDF
A COVID-19 vaccine candidate composed of the SARS-CoV-2 RBD dimer and Neisseria meningitidis outer membrane vesicles
2021 · Darielys Santana-Mederos, Rocmira Perez-Nicado, et al. · RSC Chemical Biology · 26
PDF
Open-label phase I/II clinical trial of SARS-CoV-2 receptor binding domain-tetanus toxoid conjugate vaccine (FINLAY-FR-2) in combination with receptor binding domain-protein vaccine (FINLAY-FR-1A) in children
2022 · Rinaldo Puga-Gómez, Yariset Ricardo-Delgado, et al. · International Journal of Infectious Diseases · 20
Immunogenicity and safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3–18 years old: a double-blinded, multicentre, randomised, phase 1/2 clinical trial (ISMAELILLO study)
2023 · Zurina Cinza-Estévez, Sonia Resik-Aguirre, et al. · EClinicalMedicine · 6
PDF
Cuban Vaccines Abdala and Mambisa Against Covid-19
2023 · G. Guillen, M. Limonta, et al. · International Journal of Infectious Diseases · 6
Safety and immunogenicity of anti-SARS CoV-2 conjugate vaccine SOBERANA 02 in a two-dose or three-dose heterologous scheme in adults: Phase IIb Clinical Trial
2022 · María Eugenia Toledo-Romani, Mayra García-Carmenate, et al. · medRxiv · 5
PDF
Open label phase I/II clinical trial and predicted efficacy of SARS-CoV-2 RBD protein vaccines SOBERANA 02 and SOBERANA Plus in children
2022 · Rinaldo Puga-Gómez, Yariset Ricardo-Delgado, et al. · medRxiv · 4
PDF
Tropism prediction in HIV-1 variants circulating in Cuba, 2017-2019: Implications for the pathogenesis of infection and response to Maraviroc
2023 · Anamary Suarez Batista, Lissette Perez Santos, et al. · Journal of Microbiology and Infectious Diseases · 1
Efectividad del medio de transporte viral inactivado (BioCen) para la conservación del material genético del SARS-CoV-2
2026 · Danay Carrillo Valdes, Alexis Labrada Rosado, et al. · Salud Uninorte
Seguridad, inmunogenicidad y eficacia de las vacunas SOBERANA ® 02 y SOBERANA® Plus en población pediátrica
2025 · Puga-Gómez, Rinaldo, Fonseca Hernández, Mercedes, et al. · Anales de la Academia de Ciencias de Cuba
Standardization of Viral Neutralization Assay Used in To the Determination of Neutralizing Antibodies in the Evaluation Studies of the Cuban Vaccines against COVID-19
2025 · Enrique Noa Romero, Yaday Alfonso Mirabal, et al. · Journal of Pediatrics Research Reviews & Reports
PDF
Primer brote de COVID-19 en Cuba. Factores de riesgo de morbimortalidad y respuesta específica de anticuerpos en convalecientes
2024 · Zuñiga Rosales, Yaima, Marcheco-Teruel, Beatriz, et al. · Anales de la Academia de Ciencias de Cuba
Evaluación preclínica y clínica de SOBERANA® 01. Candidato vacunal contra la COVID-19
2023 · Climent Ruiz, Yanet, Santana Mederos, Darielys, et al. · Anales de la Academia de Ciencias de Cuba
PDF
Diseño, desarrollo y evaluación preclínica de SOBERANA®02: una vacuna cubana contra COVID-19
2023 · Balbín, Yury Valdés, Mederos, Darielys Santana, et al. · HAL (Le Centre pour la Communication Scientifique Directe)
PDF
Diseño, desarrollo y evaluación preclínica de SOBERANA®02: una vacuna cubana contra COVID-19
2023 · Valdés Balbín, Yury, Santana Mederos, Darielys, et al. · Anales de la Academia de Ciencias de Cuba
PDF
SOBERANA®Plus: refuerzo seguro y eficaz de la inmunidad natural preexistente contra SARS-CoV-2
2023 · Verez Bencomo, Vicente, Ochoa Azze, Rolando, et al. · Anales de la Academia de Ciencias de Cuba
Safety and Immunogenicity of Anti-SARS-CoV-2 Conjugate Vaccine SOBERANA 02: Phase IIb Clinical Trial
2022 · Maria Eugenia-Toledo-Romani, Mayra García Carmenate, et al. · SSRN Electronic Journal
HIV/Syphilis Coinfection in Patients with Uveitis
2020 · Juliet María Enriquez Puertas, Isabel Ambou Frutos, et al. · International Journal of Research Studies in Medical and Health Sciences
PDF
Works count: 21
Citation count: 253
H-index: 6
I10-index: 6
Year
Topic
Type